Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
about
Vaccination recommendations for adult patients with rheumatic diseasesPneumococcal Vaccination in High-Risk Individuals: Are We Doing It Right?Prevention of Community-Acquired Pneumonia with Available Pneumococcal VaccinesPneumococcal Vaccination Guidance for Post-Acute and Long-Term Care Settings: Recommendations From AMDA's Infection Advisory Committee.Can Vaccinations Improve Heart Failure Outcomes?: Contemporary Data and Future Directions.Is 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Combined With 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) Superior to PPSV23 Alone for Reducing Incidence or Severity of Pneumonia in Older Adults? A Clin-IQInvasive pneumococcal disease caused by mucoid serotype 3 Streptococcus pneumoniae: a case report and literature review.Effectiveness of 23-valent pneumococcal polysaccharide vaccination in preventing community-acquired pneumonia hospitalization and severe outcomes in the elderly in SpainVaccination in the primary care setting: when is it safe to proceed?Current Recommendations for Pneumococcal Vaccination of Children and AdultsThe Saudi Thoracic Society pneumococcal vaccination guidelines-2016.Risk of hospitalization due to pneumococcal disease in adults in Spain. The CORIENNE studyRecommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid)Why the recent ACIP recommendations regarding conjugate pneumococcal vaccine in adults may be irrelevant.Streptococcus pneumoniae bacteraemia due to parotitis in a patient with systemic sclerosis and secondary Sjögren's syndrome.Pneumococcal Prevention Gets Older and Wiser.Pneumococcal conjugate vaccine use in adults.Surveillance of Vaccination Coverage among Adult Populations - United States, 2015.Impact of the Ebola outbreak on routine immunization in western area, Sierra Leone - a field survey from an Ebola epidemic area.Clinical Management of Community Acquired Pneumonia in the Elderly Patient.Pediatric portal hypertension: A review for primary carePneumonia and Streptococcus pneumoniae vaccine.Safety and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine in Adults 50 to 65 Years of Age in India: An Open-Label Trial.Public Perception of the Risks Associated with Infectious Diseases in Poland: Ebola and Influenza and Their Impact on the Attitude to Vaccination.The importance of immunization in cancer prevention, treatment, and survivorship.Community-acquired bacterial meningitis.Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - United States, 2016.Evolving Understanding of the Causes of Pneumonia in Adults, With Special Attention to the Role of Pneumococcus.Pneumococcal vaccination and chronic respiratory diseases.Pneumococcal vaccination in older persons: where are we today?Vaccination coverage and associated factors for receipt of the 23-valent pneumococcal polysaccharide vaccine in Taiwan: A nation-wide community-based study.Primary Care Physicians' Struggle with Current Adult Pneumococcal Vaccine Recommendations.Effectiveness and practical uses of 23-valent pneumococcal polysaccharide vaccine in healthy and special populations.Who to Vax: A free online tool to identify adults for pneumococcal vaccination.Effectiveness of the 13-valent pneumococcal conjugate vaccine against adult pneumonia in Italy: a case-control study in a 2-year prospective cohort.Characteristics and Management of Community-Acquired Pneumonia in the Era of Global Aging.Pneumonia in Patients with Chronic Obstructive Pulmonary Disease.Pneumococcal Conjugate Vaccine Safety in Elderly Adults.Streptococcus pneumoniae’s Virulence and Host Immunity: Aging, Diagnostics, and Prevention.Pneumococcal Meningitis Complicated by Cerebral Vasculitis, Abscess, Hydrocephalus, and Hearing Loss
P2860
Q28068286-6191A529-4B9B-4E5B-975B-0AAE00BD357BQ28070059-279F9A35-FD0B-4540-A4DF-818D65F004EFQ28077703-49032372-9E60-4B8C-B9E1-85786FA8151BQ30274913-F21EB3B7-10AD-4408-B67E-9EEC391C58F3Q31159585-F9807267-E8F3-4AF0-87D8-BA9502ADA85AQ36067387-732C8936-98D3-4333-9DC4-293D89FDFAC6Q36241461-D7DBAAFF-25D6-4225-8BEB-EAB39C1FB418Q36277159-4E113E03-3ED7-43E1-94F2-C157FF2F771EQ36507660-20DACA2D-1B9A-4CF1-8200-594A119845A4Q36555871-1E9F4856-84A6-4E58-ABAA-0BB11FC21E9BQ36861485-A5E95826-0442-4D53-9723-B708CD91BCE2Q37135456-C69E79FA-3ECE-4B1F-BC5A-C3E9E3137E87Q37135485-27138533-00EC-43B3-8D89-BEA3295B5E18Q37309186-69462D0B-D2A7-4AF6-98BB-1D5D500354B1Q37689720-06078385-5673-49D6-8474-2C10F114A32DQ38616608-660D5CCA-EDFF-4080-9B51-F28E5F931426Q38664425-5F36D717-F75A-4847-923A-50B94004312FQ38804622-9B6C1741-F009-43BC-A2AE-8C473233C772Q38818220-B60B28D2-4DB8-464A-A2AB-41D4B6D242B5Q38969066-69E4F8F3-E519-4E09-95E3-A713233612A6Q39240389-04969AEC-DC05-48B3-A878-9CD96563A9A0Q39452604-6FE745F9-81B9-4EAD-826D-7DC3AB4E04AFQ40062579-40E9C3BB-AAD6-40B6-BD31-23D5AADAF2ECQ40065437-7F7E7E94-8B60-4374-B45C-EC67878FE263Q40104207-C5B44AEA-24CC-47A3-A7F4-40D3DA849F6EQ43568749-9363DE22-D091-4082-A0C7-94268E34D32FQ43877915-A6D16FE0-390F-4B38-AB98-57484269D8CCQ44059050-A1C1439C-4941-469B-BC40-3DB077AF86AEQ47162758-F6F18589-0EE1-4689-BCAF-7F9CC0318328Q47221369-46DD806B-5B1D-4FD8-B925-02C2A032BFC2Q47547830-B10BFFAE-2B3C-4268-87B0-14C0CC52FA28Q47657870-CBBF4250-4010-467A-8464-1A6BDD130A4EQ48563045-5ED9D61A-E3D3-4749-954F-147502DD1CC1Q54568215-F3E32869-6FC0-47D3-BF54-F6C81F4D3239Q55040063-4EE835B3-C9FF-49C2-9D57-E08C5AF2336BQ55431323-A16F5B70-5DD6-4B28-9D46-CF232BAE8C2CQ55440444-8D25CAFE-4971-401B-A47E-672CD6D91C70Q55442925-A79CCAC5-A17B-425B-AF8D-0C7EE2E9BD92Q55514832-311FDBDC-3F6F-49DB-A635-48B5CAF4B036Q58551833-10013544-7F70-42FA-8024-381B178CD422
P2860
Intervals Between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Intervals Between PCV13 and PP ...... Immunization Practices (ACIP).
@en
type
label
Intervals Between PCV13 and PP ...... Immunization Practices (ACIP).
@en
prefLabel
Intervals Between PCV13 and PP ...... Immunization Practices (ACIP).
@en
P2093
P356
P1476
Intervals Between PCV13 and PP ...... Immunization Practices (ACIP).
@en
P2093
Cynthia G Whitney
Matthew R Moore
Miwako Kobayashi
Nancy M Bennett
Olivia Almendares
Ryan Gierke
Tamara Pilishvili
P304
P356
10.15585/MMWR.MM6434A4
P577
2015-09-04T00:00:00Z